Oppenheimer Sticks to Its Buy Rating for Prestige Consumer Healthcare (PBH)

In a report released yesterday, Rupesh Parikh from Oppenheimer maintained a Buy rating on Prestige Consumer Healthcare. The company’s shares closed yesterday at $69.67.

Claim 50% Off TipRanks Premium

• Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
• Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential

According to TipRanks, Parikh is a 5-star analyst with an average return of 12.1% and a 64.11% success rate. Parikh covers the Consumer Defensive sector, focusing on stocks such as Church & Dwight, Costco, and Walmart.

The word on The Street in general, suggests a Strong Buy analyst consensus rating for Prestige Consumer Healthcare with a $76.00 average price target.

Based on Prestige Consumer Healthcare’s latest earnings release for the quarter ending December 31, the company reported a quarterly revenue of $283.44 million and a net profit of $46.7 million. In comparison, last year the company earned a revenue of $290.32 million and had a net profit of $61.03 million

Based on the recent corporate insider activity of 34 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of PBH in relation to earlier this year. Earlier this month, Jeffrey Zerillo, the SVP Operations of PBH sold 1,000.00 shares for a total of $65,930.00.